Literature DB >> 8597032

Evaluation of local toxicity after repeated intranasal vaccination of guinea-pigs.

S Gizurarson1, G Georgsson, H Aggerbeck, H Thorarinsdóttir, I Heron.   

Abstract

In intranasal vaccination it is important that the adjuvant does not have any toxic effect on the sensitive nasal mucosa. In this study a histological and clinical evaluation of the effects of two different adjuvants in a vaccine containing detoxified diphtheria (DT) and tetanus toxoid (TT) in guinea pigs was done. The guinea pigs were divided in four groups and treated daily for 14 days with different formulations. Group I with saline, Groups 2 and 3 with the vaccines in a non-ionic surfactant formulation containing glycerides and Group 4 with tetraethyleneglycol formulation containing glycofurol. The guinea pigs in Groups 1, 2 and 4 were sacrificed on day 15 and Group 3, 1 week later and the tissues processed for histological examination. The animals remained healthy during the treatment and minor clinical signs, such as nose-blowing, decreased with time. The histological appearance, including the development of lymphoid tissue, was comparable in all groups. A specific toxic effect on the nasal mucosa by the different vaccine and adjuvant formulations was not observed.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8597032     DOI: 10.1016/0300-483x(95)03201-p

Source DB:  PubMed          Journal:  Toxicology        ISSN: 0300-483X            Impact factor:   4.221


  3 in total

1.  Delivery of soluble tumor necrosis factor receptor from in-situ forming PLGA implants: in-vivo.

Authors:  R E Eliaz; D Wallach; J Kost
Journal:  Pharm Res       Date:  2000-12       Impact factor: 4.200

2.  Preparation of PLGA microparticles by an emulsion-extraction process using glycofurol as polymer solvent.

Authors:  Anne Aubert-Pouëssel; Marie-Claire Venier-Julienne; Patrick Saulnier; Michelle Sergent; Jean-Pierre Benoît
Journal:  Pharm Res       Date:  2004-12       Impact factor: 4.200

3.  Intranasal immunization with pneumococcal polysaccharide conjugate vaccines protects mice against invasive pneumococcal infections.

Authors:  H Jakobsen; E Saeland; S Gizurarson; D Schulz; I Jónsdóttir
Journal:  Infect Immun       Date:  1999-08       Impact factor: 3.441

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.